<p>Praxis Investment Management Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在强生（NYSE:JNJ - 免费报告）的持仓减少了 24.0%。该机构投资者在此期间出售了 15,670 股后，持有 49,661 股该公司的股票。强生约占 Praxis Investment Management Inc.投资组合的 0.5%，是其第 29 大持仓。Praxis Investment Management Inc.在强生的持股在最近的报告期末价值为 7,586,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>强生的并购策略才是投资者真正关注的故事</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也增加或减少了对该公司的持股。Commons Capital LLC 在第二季度将其在强生的持仓增加了 19.0%。Commons Capital LLC 目前持有 1,826 股该公司的股票，价值 279,000 美元，此前在上个季度又购买了 291 股。Harbor Asset Planning Inc.在第二季度获得了强生的新持仓，价值约为 142,000 美元。Werba Rubin Papier Wealth Management 在第二季度将其在强生的持仓增加了 19.5%。Werba Rubin Papier Wealth Management 目前持有 2,892 股该公司的股票，价值 442,000 美元，此前在上个季度又购买了 471 股。Turtle Creek Wealth Advisors LLC 在第二季度获得了强生的新持仓，价值约为 1,224,000 美元。最后，WealthPlan Investment Management LLC 在第二季度将其在强生的持仓增加了 20.2%。WealthPlan Investment Management LLC 目前持有 70,070 股该公司的股票，价值 10,703,000 美元，此前在上个季度又购买了 11,759 股。目前 69.55% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师升级和降级</h2>
<p>强生的股票曾多次成为研究分析师报告的主题。Cowen 在周二的研究报告中重申了对强生股票的 “买入” 评级。富国银行在 10 月 3 日的研究报告中对强生股票设定了 212.00 美元的目标价，并给予该股票 “超配” 评级。摩根士丹利在周三的研究报告中对强生股票设定了 190.00 美元的目标价。巴克莱在 7 月 17 日的研究报告中将强生股票的目标价从 165.00 美元提高至 176.00 美元，并给予该股票 “持平” 评级。最后，Stifel Nicolaus 在周三的研究报告中将强生股票的目标价从 165.00 美元提高至 190.00 美元，并给予该股票 “持有” 评级。两位股票研究分析师对该股票给予了强烈买入评级，十二位给予了买入评级，八位给予了持有评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 199.59 美元。</p>
<ul>
<li>强生股票可以继续上涨，因为战略奏效</li>
</ul>
<p><strong>查看我们关于 JNJ 的最新报告</strong></p>
<h2>内部人士买卖</h2>
<p>在其他消息中，执行副总裁 Jennifer L. Taubert 在 9 月 4 日（星期四）出售了 56,471 股该公司的股票。股票以 177.81 美元的平均价格出售，总价值为 10,041,108.51 美元。交易完成后，该执行副总裁持有 178,013 股公司股票，价值 31,652,491.53 美元。这代表其持股减少了 24.08%。该交易已在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。内部人士持有该公司 0.16% 的股票。</p>
<h2>强生股票上涨 0.6%</h2>
<ul>
<li>为什么 AbbVie 和强生可能会超越辉瑞</li>
</ul>
<p>强生在周五的开盘价为 193.27 美元。该公司的债务与股本比率为 0.50，流动比率为 1.01，速动比率为 0.76。该公司的市值为 4654.5 亿美元，市盈率为 18.65，市盈增长比率为 2.27，贝塔系数为 0.40。该公司有 50 日简单移动平均线为 180.49 美元，200 日简单移动平均线为 164.86 美元。强生的 52 周低点为 140.68 美元，52 周高点为 194.40 美元。</p>
<p>强生（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日（星期三）发布了季度财报。该公司报告本季度每股收益为 2.26 美元。该业务在本季度的收入为 240.2 亿美元。强生的净利润率为 27.26%，股本回报率为 33.08%。平均而言，卖方分析师预计强生在当前年度的每股收益为 10.58 美元。</p>
<h2>强生宣布分红</h2>
<p>该公司最近还宣布了季度分红，将于 12 月 9 日（星期二）支付。11 月 25 日（星期二）的股东将获得 1.30 美元的分红。这代表每年 5.20 美元的分红和 2.7% 的收益率。该分红的除息日为 11 月 25 日（星期二）。强生的分红支付比率目前为 50.19%。</p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过强生</li>
<li>目前有哪些值得购买的大盘股？</li>
<li>强生的并购策略才是投资者真正需要关注的故事</li>
<li>如何开始投资于便士股票</li>
<li>特斯拉：一些分析师预测将下跌 30%——该恐慌了吗？</li>
<li>科技股解析：你需要了解的科技知识</li>
<li>对美元的对冲基金态度转变——这三只股票的买入信号？</li>
</ul>
<p><strong>想看看其他对强生持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Praxis Investment Management Inc. 在第二季度将其在强生（NYSE: JNJ）的持股减少了 24%，目前持有 49,661 股，价值约 759 万美元。该头寸占其投资组合的约 0.5%。其他机构投资者也调整了他们的持股，其中 Commons Capital LLC 和 WealthPlan Investment Management LLC 的增持尤为显著。分析师对 JNJ 保持总体积极的展望，普遍目标价为 199.59 美元，评级从强烈买入到持有不等</p>

<p>Praxis Investment Management Inc. cut its position in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 24.0% during the second quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 49,661 shares of the company's stock after selling 15,670 shares during the period. Johnson &amp; Johnson accounts for about 0.5% of Praxis Investment Management Inc.'s investment portfolio, making the stock its 29th biggest position. Praxis Investment Management Inc.'s holdings in Johnson &amp; Johnson were worth $7,586,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Praxis Investment Management Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在强生（NYSE:JNJ - 免费报告）的持仓减少了 24.0%。该机构投资者在此期间出售了 15,670 股后，持有 49,661 股该公司的股票。强生约占 Praxis Investment Management Inc.投资组合的 0.5%，是其第 29 大持仓。Praxis Investment Management Inc.在强生的持股在最近的报告期末价值为 7,586,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>强生的并购策略才是投资者真正关注的故事</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Commons Capital LLC boosted its position in Johnson &amp; Johnson by 19.0% in the second quarter. Commons Capital LLC now owns 1,826 shares of the company's stock valued at $279,000 after buying an additional 291 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in Johnson &amp; Johnson in the second quarter valued at about $142,000. Werba Rubin Papier Wealth Management boosted its position in Johnson &amp; Johnson by 19.5% in the second quarter. Werba Rubin Papier Wealth Management now owns 2,892 shares of the company's stock valued at $442,000 after buying an additional 471 shares in the last quarter. Turtle Creek Wealth Advisors LLC acquired a new position in Johnson &amp; Johnson in the second quarter valued at about $1,224,000. Finally, WealthPlan Investment Management LLC boosted its position in Johnson &amp; Johnson by 20.2% in the second quarter. WealthPlan Investment Management LLC now owns 70,070 shares of the company's stock valued at $10,703,000 after buying an additional 11,759 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也增加或减少了对该公司的持股。Commons Capital LLC 在第二季度将其在强生的持仓增加了 19.0%。Commons Capital LLC 目前持有 1,826 股该公司的股票，价值 279,000 美元，此前在上个季度又购买了 291 股。Harbor Asset Planning Inc.在第二季度获得了强生的新持仓，价值约为 142,000 美元。Werba Rubin Papier Wealth Management 在第二季度将其在强生的持仓增加了 19.5%。Werba Rubin Papier Wealth Management 目前持有 2,892 股该公司的股票，价值 442,000 美元，此前在上个季度又购买了 471 股。Turtle Creek Wealth Advisors LLC 在第二季度获得了强生的新持仓，价值约为 1,224,000 美元。最后，WealthPlan Investment Management LLC 在第二季度将其在强生的持仓增加了 20.2%。WealthPlan Investment Management LLC 目前持有 70,070 股该公司的股票，价值 10,703,000 美元，此前在上个季度又购买了 11,759 股。目前 69.55% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>JNJ has been the subject of a number of research analyst reports. Cowen reaffirmed a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research note on Tuesday. Wells Fargo &amp; Company set a $212.00 target price on shares of Johnson &amp; Johnson and gave the stock an &#34;overweight&#34; rating in a research note on Friday, October 3rd. Morgan Stanley set a $190.00 target price on shares of Johnson &amp; Johnson in a research note on Wednesday. Barclays boosted their target price on shares of Johnson &amp; Johnson from $165.00 to $176.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Finally, Stifel Nicolaus boosted their target price on shares of Johnson &amp; Johnson from $165.00 to $190.00 and gave the stock a &#34;hold&#34; rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $199.59.</p>
<div class="lb-trans"><p>强生的股票曾多次成为研究分析师报告的主题。Cowen 在周二的研究报告中重申了对强生股票的 “买入” 评级。富国银行在 10 月 3 日的研究报告中对强生股票设定了 212.00 美元的目标价，并给予该股票 “超配” 评级。摩根士丹利在周三的研究报告中对强生股票设定了 190.00 美元的目标价。巴克莱在 7 月 17 日的研究报告中将强生股票的目标价从 165.00 美元提高至 176.00 美元，并给予该股票 “持平” 评级。最后，Stifel Nicolaus 在周三的研究报告中将强生股票的目标价从 165.00 美元提高至 190.00 美元，并给予该股票 “持有” 评级。两位股票研究分析师对该股票给予了强烈买入评级，十二位给予了买入评级，八位给予了持有评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 199.59 美元。</p>
</div><ul>
<li>Johnson &amp; Johnson Stock Can Keep Rising as Strategy Pays Off</li>
</ul>
<div class="lb-trans"><ul>
<li>强生股票可以继续上涨，因为战略奏效</li>
</ul>
</div><p><strong>View Our Latest Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 JNJ 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Jennifer L. Taubert 在 9 月 4 日（星期四）出售了 56,471 股该公司的股票。股票以 177.81 美元的平均价格出售，总价值为 10,041,108.51 美元。交易完成后，该执行副总裁持有 178,013 股公司股票，价值 31,652,491.53 美元。这代表其持股减少了 24.08%。该交易已在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。内部人士持有该公司 0.16% 的股票。</p>
</div><h2>Johnson &amp; Johnson Trading Up 0.6%</h2>
<div class="lb-trans"><h2>强生股票上涨 0.6%</h2>
</div><ul>
<li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 AbbVie 和强生可能会超越辉瑞</li>
</ul>
</div><p>JNJ opened at $193.27 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $465.45 billion, a price-to-earnings ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The firm has a 50 day simple moving average of $180.49 and a 200 day simple moving average of $164.86. Johnson &amp; Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40.</p>
<div class="lb-trans"><p>强生在周五的开盘价为 193.27 美元。该公司的债务与股本比率为 0.50，流动比率为 1.01，速动比率为 0.76。该公司的市值为 4654.5 亿美元，市盈率为 18.65，市盈增长比率为 2.27，贝塔系数为 0.40。该公司有 50 日简单移动平均线为 180.49 美元，200 日简单移动平均线为 164.86 美元。强生的 52 周低点为 140.68 美元，52 周高点为 194.40 美元。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 33.08%. On average, sell-side analysts anticipate that Johnson &amp; Johnson will post 10.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日（星期三）发布了季度财报。该公司报告本季度每股收益为 2.26 美元。该业务在本季度的收入为 240.2 亿美元。强生的净利润率为 27.26%，股本回报率为 33.08%。平均而言，卖方分析师预计强生在当前年度的每股收益为 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio is presently 50.19%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，将于 12 月 9 日（星期二）支付。11 月 25 日（星期二）的股东将获得 1.30 美元的分红。这代表每年 5.20 美元的分红和 2.7% 的收益率。该分红的除息日为 11 月 25 日（星期二）。强生的分红支付比率目前为 50.19%。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>How to start investing in penny stocks</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过强生</li>
<li>目前有哪些值得购买的大盘股？</li>
<li>强生的并购策略才是投资者真正需要关注的故事</li>
<li>如何开始投资于便士股票</li>
<li>特斯拉：一些分析师预测将下跌 30%——该恐慌了吗？</li>
<li>科技股解析：你需要了解的科技知识</li>
<li>对美元的对冲基金态度转变——这三只股票的买入信号？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对强生持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Praxis Investment Management Inc. 在强生公司 $JNJ 中持有 759 万美元的股份